skip to main content


Global Venture Capital Firm Finances Medical Advancement

Canaan Partners

Successfully represented Canaan Partners as the lead investor in connection with the Series B Preferred Stock financing of CytomX  Therapeutics. The $41 million financing round will support CytomX’s  Probody ™ Platform, a proprietary technology for developing highly targeted antibody therapeutics.

© Shipman & Goodwin LLP 2020. All Rights Reserved.